# Effects of Fenofibrate Therapy in Diabetic Nephropathy

Study · id `cardio:ct-nct03869931` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03869931](<https://clinicaltrials.gov/study/NCT03869931>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03869931

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT03869931. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-08 (actual); primary completion 2021-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT03869931, source copy `cardio:ctgov-nct03869931-2020-12-14`, retrieved 2026-10-26)
- Started: 2019-03-08 (actual) (ClinicalTrials.gov record NCT03869931, source copy `cardio:ctgov-nct03869931-2020-12-14`, retrieved 2026-10-26)
- Primary completion: 2021-04-30 (anticipated) (ClinicalTrials.gov record NCT03869931, source copy `cardio:ctgov-nct03869931-2020-12-14`, retrieved 2026-10-26)
- Completion: 2021-04-30 (anticipated) (ClinicalTrials.gov record NCT03869931, source copy `cardio:ctgov-nct03869931-2020-12-14`, retrieved 2026-10-26)
- Countries: Singapore (ClinicalTrials.gov record NCT03869931, source copy `cardio:ctgov-nct03869931-2020-12-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03869931-2020-12-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Fenofibrate Therapy in Diabetic Nephropathy
- Condition: Diabetes Mellitus
- Condition: Diabetic Nephropathies
- Intervention (Drug): Fenofibrate
- Lead sponsor: Singapore General Hospital
- Lead sponsor class: OTHER
- Collaborator: National Medical Research Council (NMRC), Singapore
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Singapore General Hospital (`cardio:org-singapore-general-hospital`)
- Registry lists this organization as a collaborator: National Medical Research Council (NMRC), Singapore (`cardio:org-national-medical-research-council-nmrc-singapore`)

## Provenance

Content hash: a73eedab1b1895e42b1c23c79156c1087c8bcc3608318360735cd769daa8fbdb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
